X4 Pharmaceuticals, Inc (XFOR) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$3.35

From 52W high−30.62%

Volume535539.00

Market cap$321.24M

P/E (TTM)—

P/S (TTM)20.3x

Div yield—

Key dataNov 4, 2026

Open

$3.35

From 52W high

−30.62%

Volume

535539.00

Market cap

$321.24M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.4x

P/E (TTM)

—

RSI (14)

49.9

MomentumView details →

1D Return

+2.21%

YTD Return

−21.38%

SummaryUpdated Jun 1, 2026

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a late-stage clinical biopharmaceutical company founded in 2010 and headquartered in Boston, Massachusetts. The company went public in November 2017 and focuses on developing novel therapeutics for rare diseases. X4 Pharmaceuticals achieved a significant milestone in 2024 with the FDA approval and commercial launch of its lead drug XOLREMDI (mavorixafor) for WHIM syndrome, marking its transition from a pure development-stage company to a commercial-stage biopharmaceutical enterprise.

Ask drillr about X4 Pharmaceuticals, Inc →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−2.4x

EV/Sales

12.0x

P/S (TTM)

20.3x

P/B (TTM)

2.1x

ProfitabilityView details →

Gross Margin

81.22%

Net Margin

−568.80%

EBITDA Margin

−503.31%

ROE (TTM)

−57.98%

ROA (TTM)

−35.62%

Asset Turnover

0.06x

GrowthView details →

Revenue YoY

−51.65%

EPS YoY

+91.91%

FCF YoY

—

Revenue CAGR 3Y

+1273.21%

EPS CAGR 3Y

+66.55%

EBITDA YoY

+12.45%

MomentumView details →

1D Return

+2.21%

YTD Return

−21.38%

1Y Return

−11.41%

RSI (14)

49.9

vs 50D SMA

−3.98%

vs 200D SMA

−17.12%

Capital & dividendView details →

Debt/Equity

0.50x

Current Ratio

11.30x

Quick Ratio

11.02x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.13

EPS Surprise

26.14%

Beats (12Q)

8/12

Next Q EPS Est

−$0.19

Avg Surprise (4Q)

19.52%

Rev Surprise

263.88%

Financials snapshotView financials →

Revenue (TTM)

15.85M

Net Income (TTM)

−90.14M

Op. CF (TTM)

−83.74M

Next earningsMar 23, 2027 →

Latest newsMore news →

X4 Pharmaceuticals, Inc said its 4WARD Phase 3 chronic neutropenia trial is expected to reach target enrollment in the fourth quarter of 2026.4h ago

X4 Pharmaceuticals, Inc reported its third-quarter 2026 financial results.4h ago

Similar companies

Kyverna Therapeutics, Inc.KYTX Benitec Biopharma Inc.BNTC Scribe Therapeutics Inc.SCTX Prelude Therapeutics IncorporatedPRLD Agenus Inc.AGEN Transcenta Holding Limited06628.HK Find similar companies →

Latest newsMore news →

X4 Pharmaceuticals, Inc said its 4WARD Phase 3 chronic neutropenia trial is expected to reach target enrollment in the fourth quarter of 2026.4h ago X4 Pharmaceuticals, Inc reported its third-quarter 2026 financial results.4h ago